Get the Stockscreener App
10.50
0.57%
-0.06
After Hours:
10.50
Alvotech stock is traded at $10.50, with a volume of 288.17K.
It is down -0.57% in the last 24 hours and up +23.09% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$10.56
Open:
$10.61
24h Volume:
288.17K
Relative Volume:
1.85
Market Cap:
$2.40B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-5.6757
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
+32.24%
1M Performance:
+23.09%
6M Performance:
-13.01%
1Y Performance:
-21.35%
1-Day Range:
$10.42
$10.81
1-Week Range:
$9.0301
$10.81
52-Week Range:
$7.35
$14.65
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
10.50 | 2.40B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
154.92 | 69.45B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.40 | 48.49B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 47.40B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.89 | 20.19B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
299.68 | 13.84B | 2.99B | 1.21B | 1.13B | 25.06 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech at BofA Securities Healthcare Conference: Strategic Biosimilar Focus By Investing.com - Investing.com India
Alvogen Lux Holdings Acquires 210,000 Shares in Alvotech at ISK 1,277.38 - Nasdaq
Transactions of Managers and Closely Associated Persons - marketscreener.com
Alvotech Raises 2025 Revenue Guidance Amid Strong Performance - TipRanks
Teva, Alvotech receive FDA nod for interchangeability of Selardsdi with Stelara - Drug Store News
Analyst Estimates: Here's What Brokers Think Of Alvotech (NASDAQ:ALVO) After Its First-Quarter Report - Yahoo Finance
Alvotech CEO Acquires Significant Shareholding, Strengthening Market Confidence - TipRanks
Is Alvotech (ALVO) The Best Stock That Will Bounce Back? - Insider Monkey
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada - The Manila Times
Alvotech Reports Strong Q1 2025 Earnings Growth - TipRanks
Alvotech earnings beat by $0.32, revenue topped estimates - Investing.com Nigeria
Alvotech sees minimal impact on 2025 product revenues from tariffs - MSN
Transcript : Alvotech, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday - Benzinga
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT - marketscreener.com
Alvotech Reports Robust Q1 2025 Growth and Strategic Expansions - TipRanks
ACM Research Reports First Quarter 2025 Results - Stock Titan
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm - The Manila Times
Alvotech Q1 2025 Earnings Call Transcript - MarketBeat
Alvotech (NASDAQ:ALVO) Sees Significant Growth in Short Interest - MarketBeat
Alvotech shares surge 6.6% as Q1 results top estimates By Investing.com - Investing.com Nigeria
Alvotech shares surge 6.6% as Q1 results top estimates - Investing.com
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update - The Manila Times
Alvotech Anticipates Minimal Impact from Potential U.S. Tariffs on Imported Pharmaceuticals in 2025 - Nasdaq
Alvotech Sees Minimal Impact On 2025 Revenues From U.S. Tariffs - marketscreener.com
Alvotech : Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 - marketscreener.com
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 - The Manila Times
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 - Yahoo Home
Teva, Alvotech get FDA nod for Johnson & Johnson biosimilar - MSN
Teva And Alvotech Celebrate Interchangeability For US Ustekinumab - insights.citeline.com
FDA approves Teva-Alvotech biosimilar Selarsdi for multiple conditions - World Pharmaceutical Frontiers
Alvotech SA expected to post a loss of 11 cents a shareEarnings Preview - TradingView
FDA Approves SELARSDI from Alvotech (ALVO) as Interchangeable Bi - GuruFocus
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? - Benzinga
Teva, Alvotech announce FDA approval of interchangeability for SELARSDI - TipRanks
US FDA Approves Alvotech's Selarsdi for Full Interchangeability with J&J's Stelara - marketscreener.com
Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Nigeria
Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com Australia
Teva, Alvotech: FDA approves interchangeability for SELARSDI with Stelara - TipRanks
Alvotech’s SELARSDI Gains FDA Approval for Interchangeability with Stelara - TipRanks
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) | TEVA Stock News - GuruFocus
Teva, Alvotech Get FDA Approval for Selarsdi's Interchangeablity With Stelara - marketscreener.com
Teva and Alvotech Announce FDA Approval of - GlobeNewswire
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) - finanzen.ch
FDA Grants Full Interchangeability to New Stelara Biosimilar for Multiple Autoimmune Conditions - Stock Titan
FDA Approval Boosts Alvotech's (ALVO) SELARSDI as Interchangeabl - GuruFocus
Alvotech to Announce Q1 2025 Financial Results on May 7, 2025, with Conference Call on May 8, 2025 - Nasdaq
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) - The Manila Times
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14 - marketscreener.com
REG-Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) - TradingView
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):